KCM
PVCT

Knoll Capital Management’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Knoll Capital Management’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200,000
Closed -$160K – 19
2014
Q4 		$160K Hold
200,000
– – 0.06% 13
2014
Q3 		$204K Hold
200,000
– – 0.08% 13
2014
Q2 		$172K Buy
+200,000
New +$240K 0.08% 12

Other funds holding PVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Knoll Capital Management's PVCT Position: Q1 2015 in Review

Knoll Capital Management sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q1 2015, closing a stake of 200,000 shares — an estimated $160K sold.

Knoll Capital Management first reported a position in PVCT in Q2 2014 and held it in 3 quarters. The position peaked at $204K in Q3 2014. 35 funds tracked by Wall St. Rank hold PVCT as of Q1 2015.

  • Knoll Capital Management reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q1 2015 after selling out during the quarter.
  • Knoll Capital Management sold 200,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q1 2015, an estimated $160K.
  • Knoll Capital Management first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 3 quarters.
  • Knoll Capital Management's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $204K in Q3 2014.
  • 35 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q1 2015.

Based on Knoll Capital Management's 13F filing for Q1 2015, filed 15 May 2015.